Furlanut M - Search Results

1

Therapeutic drug monitoring-guided high teicoplanin dosage regimen required to treat a hypoalbuminemic renal transplant patient undergoing continuous venovenous hemofiltration.

Pea F, Brollo L, Lugano M, Dal Pos L, Furlanut M. Pea F, et al. Among authors: furlanut m. Ther Drug Monit. 2001 Oct;23(5):587-8. doi: 10.1097/00007691-200110000-00013. Ther Drug Monit. 2001. PMID: 11591906 No abstract available.

2

Systemic vancomycin overexposure in a patient with spinal cord injury who had Staphylococcal sepsis and Clostridium difficile colitis.

Pea F, Furlanut M, Bianchi L. Pea F, et al. Among authors: furlanut m. Ther Drug Monit. 2000 Apr;22(2):233-4. doi: 10.1097/00007691-200004000-00017. Ther Drug Monit. 2000. PMID: 10774640 No abstract available.

3

Ciprofloxacin disposition in elderly patients with LRTI being treated with sequential therapy (200 mg intravenously twice daily followed by 500 mg per os twice daily): comparative pharmacokinetics and the role of therapeutic drug monitoring.

Pea F, Milaneschi R, Baraldo M, Lugatti E, Talmassons G, Furlanut M. Pea F, et al. Among authors: furlanut m. Ther Drug Monit. 2000 Aug;22(4):386-91. doi: 10.1097/00007691-200008000-00004. Ther Drug Monit. 2000. PMID: 10942176

4

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.

Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Pea F, et al. Among authors: furlanut m. J Antimicrob Chemother. 2003 Apr;51(4):971-5. doi: 10.1093/jac/dkg147. Epub 2003 Feb 25. J Antimicrob Chemother. 2003. PMID: 12654757

5

Blood concentrations and clinical effect of cyclosporin in psoriasis.

Furlanut M, Baraldo M, Pea F, Marzocchi V, Croattino L, Galla F. Furlanut M, et al. Ther Drug Monit. 1996 Oct;18(5):544-8. doi: 10.1097/00007691-199610000-00004. Ther Drug Monit. 1996. PMID: 8885117 Clinical Trial.

6

Antimicrobial agents in elective surgery: prophylaxis or "early therapy"?

Pea F, Viale P, Furlanut MI. Pea F, et al. Among authors: furlanut mi. J Chemother. 2003 Feb;15(1):3-11. doi: 10.1179/joc.2003.15.Supplement-2.3. J Chemother. 2003. PMID: 12678408 Review.

7

Linezolid disposition after standard dosages in critically ill patients undergoing continuous venovenous hemofiltration: a report of 2 cases.

Pea F, Viale P, Lugano M, Pavan F, Scudeller L, Della Rocca G, Furlanut M. Pea F, et al. Among authors: furlanut m. Am J Kidney Dis. 2004 Dec;44(6):1097-102. doi: 10.1053/j.ajkd.2004.08.032. Am J Kidney Dis. 2004. PMID: 15558532

8

Levofloxacin PK/PD: from sequential therapy model to high dosage for critical patients.

Pea F, Furlanut M. Pea F, et al. Among authors: furlanut m. J Chemother. 2004 Apr;16 Suppl 2:8-10. doi: 10.1080/1120009x.2004.11782366. J Chemother. 2004. PMID: 15255555 Review. No abstract available.

9

Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Pea F, Furlanut M. Pea F, et al. Among authors: furlanut m. Clin Pharmacokinet. 2001;40(11):833-68. doi: 10.2165/00003088-200140110-00004. Clin Pharmacokinet. 2001. PMID: 11735605 Review.

10

Urinary pharmacokinetics and theoretical pharmacodynamics of intravenous levofloxacin in intensive care unit patients treated with 500 mg b.i.d. for ventilator-associated pneumonia.

Pea F, Pavan F, Di Qual E, Brollo L, Nascimben E, Baldassarre M, Furlanut M. Pea F, et al. Among authors: furlanut m. J Chemother. 2003 Dec;15(6):563-7. doi: 10.1179/joc.2003.15.6.563. J Chemother. 2003. PMID: 14998081

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

137 results

Search Page

Filters